-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on AnaptysBio, Raises Price Target to $75

Benzinga·03/12/2026 15:19:59
Listen to the news
Wedbush analyst Martin Fan maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and raises the price target from $60 to $75.